Design and characterization

[1]  M. Lethem,et al.  The origin of DNA associated with mucus glycoproteins in cystic fibrosis sputum. , 1990, The European respiratory journal.

[2]  N. Hodges,et al.  Protection of Pseudomonas aeruginosa against ciprofloxacin and beta-lactams by homologous alginate , 1991, Antimicrobial Agents and Chemotherapy.

[3]  F. Ratjen,et al.  Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis , 2001, The Lancet.

[4]  L. Delattre,et al.  Solid lipid microparticles as a sustained release system for pulmonary drug delivery. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[5]  J. Emerson,et al.  Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis , 2007, Pediatric pulmonology.

[6]  Xiuli Wang,et al.  Solid lipid nanoparticles for pulmonary delivery of insulin. , 2008, International journal of pharmaceutics.

[7]  D. Geller,et al.  New aerosol delivery devices for cystic fibrosis. , 2009, Respiratory care.

[8]  R. Neale,et al.  Development of the First Inhaled Antibiotic for the Treatment of Cystic Fibrosis , 2010, Science Translational Medicine.

[9]  A. Zychlinsky,et al.  Neutrophil Elastase Enhances Sputum Solubilization in Cystic Fibrosis Patients Receiving DNase Therapy , 2011, PloS one.

[10]  Anders Folkesson,et al.  Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: an evolutionary perspective , 2012, Nature Reviews Microbiology.

[11]  P. Belliveau,et al.  Inhaled Aztreonam Lysine for Cystic Fibrosis Pulmonary Disease–Related Outcomes , 2012, The Annals of pharmacotherapy.

[12]  N. Høiby,et al.  Phenotypes selected during chronic lung infection in cystic fibrosis patients: implications for the treatment of Pseudomonas aeruginosa biofilm infections. , 2012, FEMS immunology and medical microbiology.

[13]  J. Elborn,et al.  Treatment of lung infection in patients with cystic fibrosis: current and future strategies. , 2012, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[14]  J. Varshosaz,et al.  Biodistribution of Amikacin Solid Lipid Nanoparticles after Pulmonary Delivery , 2013, BioMed research international.

[15]  R. Hartmann,et al.  Antibiotic-free nanotherapeutics: ultra-small, mucus-penetrating solid lipid nanoparticles enhance the pulmonary delivery and anti-virulence efficacy of novel quorum sensing inhibitors. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[16]  Garry R. Cutting,et al.  Cystic fibrosis genetics: from molecular understanding to clinical application , 2014, Nature Reviews Genetics.

[17]  B. Tümmler,et al.  Origins of cystic fibrosis lung disease. , 2015, The New England journal of medicine.